溶瘤病毒
胰腺癌
医学
溶瘤腺病毒
放射治疗
癌症
肿瘤微环境
癌症研究
肿瘤科
化疗
内科学
作者
A-Rum Yoon,Jae‐Keun Hong,Bo‐Kyeong Jung,Hyomin Ahn,S. N. Zhang,Chae‐Ok Yun
出处
期刊:Cancer Letters
[Elsevier]
日期:2023-11-01
卷期号:579: 216456-216456
被引量:1
标识
DOI:10.1016/j.canlet.2023.216456
摘要
Pancreatic cancer remains one of the deadliest cancers with extremely high mortality rate, and the number of cases is expected to steadily increase with time. Pancreatic cancer is refractory to conventional cancer treatment options, like chemotherapy and radiotherapy, and commercialized immunotherapeutics, owing to its immunosuppressive and desmoplastic phenotype. Due to these reasons, development of an innovative treatment option that can overcome these challenges posed by the pancreatic tumor microenvironment (TME) is in an urgent need. The present review aims to summarize the evolution of oncolytic adenovirus (oAd) engineering and usage as therapeutics (either monotherapy or combination therapy) over the last decade to overcome these hurdles to instigate a potent antitumor effect against desmoplastic and immunosuppressive pancreatic cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI